RESPONSE OF BUPROPION IN COMBINATION OF COGNITIVE BEHAVIORAL THERAPY IN SMOKING CESSATION AMONG CARDIAC DISEASE PATIENTS.

Abstract

ABSTRACT
BACKGROUND: The purpose of the trial is to assess the efficacy and safety of using
bupropion in conjunction with cognitive-behavioral therapy (CBT) to help individuals with
cardiac illness quit smoking. METHODOLOGY: A total of 40 individuals were split into two
groups for a randomized controlled experiment, with group A getting bupropion and cognitive
behavioral therapy (CBT) and group B receiving a placebo and CBT. While participants in the
control group got a placebo and the same number of CBT sessions, those in the treatment group
received bupropion for 7–12 weeks. RESULTS: Analysis of the findings was based on tobacco
craving index and complete blood count of participants performed at two different interval that
were at baseline and after completion of 12 weeks of treatment protocol and the results had
provided evidences that at baseline tobacco craving index of participants in group A at baseline
for level of craving was 2.55±0.51 that was reduced to 1.15±0.58 and the frequency had fallen
from 2.5±0.51 to 0.9±0.71 cigarettes daily. In group B the values of tobacco craving index for
level of craving at baseline was 2.55±0.51 that went down to 1.75±0.71 and frequency of
cigarettes per day reduced from 2.6±0.5 to 1.45±0.6 CONCLUSION: Overall, the study
indicates that bupropion plus CBT may be helpful in helping individuals with cardiac illness quit
smoking, but they were not shown to be superior to CBT alone. It may be necessary to do more
research with a bigger sample size and a longer follow-up time to substantiate the combo
therapy's efficacy.